Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects more than 15% of the population over the age of 60 in China. About 15% patients with MCI could progress into dementia after two years and about one-third develop into dementia within five years, which will lead to suffering, as well as staggering economic and care burden. So, exploring the predicting biomarkers from MCI to dementia to identify and delay progression to dementia at an early stage is of great social and clinical significance. Some reports based on a single neural biomarker suggest that risk models can predict the conversion of MCI to dementia, but no widely recognized prediction models basing on multiple complex markers have been used in clinical practice. The objectives of this study are to outline the spectrum of MCI transforming into dementia through a 5-year prospective longitudinal cohort study; Secondly, screening biomarkers for MCI transmit to dementia are based on clinical symptoms, neuropsychology, neuroimaging, neuroelectrophysiology, and humoral markers tests data.

开始日期2023-02-28

申办/合作机构

首都医科大学宣武医院

[+4]

ChiCTR2200066965

/ Suspended早期临床1期IIT

Clinical study on cooperative treatment of Alzheimer's disease based on multi-target

开始日期2023-01-01

申办/合作机构

大连大学附属中山医院

100 项与大连大学附属中山医院相关的临床结果

登录后查看更多信息

0 项与大连大学附属中山医院相关的专利（医药）

登录后查看更多信息

1,106

项与大连大学附属中山医院相关的文献（医药）

2025-04-01·CURRENT CANCER DRUG TARGETS

Low Expression of GRIM-19 Correlates with Poor Prognosis in Patients with Upper Urinary Tract Urothelial Carcinoma

Article

作者: Sun, Weibing ; Tian, Feng ; Lv, Long ; Jiang, Fengze ; Guan, Sheng ; Jiang, Sixiong ; Wang, Qi ; Kalvakolanu, Dhan V ; Liu, Zonglin

Purpose::

This study aimed to clarify the expression of a gene associated with Retinoid- Interferon-Induced Mortality-19 (GRIM-19) in Upper Urinary Tract Urothelial Carcinoma (UUTUC) and its prognostic significance for UUTUC patients.

Materials and Methods::

Immunohistochemical (IHC) staining was used to determine the GRIM-19 expression in 70 paired samples. Progression-Free Survival (PFS) and Cancer-Specific Survival (CSS) were assessed using the Kaplan-Meier method. The independent prognostic factors for PFS and CSS were analyzed by multivariable Cox regression models.

Results::

IHC staining showed that GRIM-19 expression was significantly decreased in UUTUC, and its cellular location changed from being both cytoplasmic and nuclear to only cytoplasmic. Kaplan- Meier analysis revealed that the patients with tumors expressing low GRIM-19 had a significantly higher risk for tumor progression (P = 0.002) and cancer-specific mortality (P < 0.001) compared to those with high GRIM-19 levels. The Cox regression showed that both GRIM-19 expression (P = 0.025) and lymph node metastasis (LN) (P = 0.007) were independent predictors of progression in the muscle-invasive (MIC) subgroup. GRIM-19 expressions (entire cohort: P = 0.011; MIC subgroup: P = 0.025), LN (entire cohort: P = 0.019; MIC subgroup: P = 0.007), and progression (entire cohort: P < 0.001; MIC subgroup: P < 0.001) were independent predictors of cancer-specific survival.

Conclusion::

Low expression of GRIM-19 in patients with UUTUC had significantly shorter PFS or CSS compared to those with high GRIM-19-expressing tumors. High GRIM-19 expression was also strongly associated with longer PFS in MIC patients. It indicates that GRIM-19 might serve as a promising prognostic biomarker for UUTUC patients.

2025-03-01·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Biological agents as attractive targets for inflammatory bowel disease therapeutics

Review

作者: Zhao, Yu-Wei ; Xue, Jia-Chen ; Hou, Xiao-Ting ; Yuan, Shuo

Inflammatory bowel disease (IBD) refers to a group of chronic, recurrent intestinal inflammatory conditions with a complex cause and unclear underlying mechanisms. It includes two main types: Ulcerative colitis (UC) and Crohn's disease (CD). The conventional treatment of IBD mainly includes 5-aminosalicylates, glucocorticoids, and immunosuppressive drugs, which have their limitations. Recent advancements in IBD research have expanded treatment options, with biological agents playing a key role. Anti-tumor necrosis factor alpha has emerged as the first-line therapy for moderate to severe IBD. Anti-integrin antibodies have also become important for the treatment, and vedolizumab is often used in cases of anti-tumor necrosis factor-alpha failure and intolerance to other treatments. Other biological agents are being tested in clinical trials at different stages. This article reviews the efficacy and safety of the primary biological therapies for IBD and provides a comprehensive analysis of the current clinical challenges associated with the disease.

2025-03-01·Journal of Materials Research and Technology-JMR&T

Effect of Mn on microstructures and properties of backward extruded Zn-0.5 Mg alloys

作者: Ren, Yuping ; Liu, Baoyi ; Su, Yun ; Meng, Dehui ; Zhang, Haochun ; Xiao, Chi ; Sun, Shineng ; Zheng, Yiheng

Zn-based alloys have gradually attracted extensive concern due to its suitable degradation rate and good biocompatibility.These alloys have become a new type of biodegradable material following Mg-based alloys and Fe-based alloys.However, the mech. properties of pure Zn are poor, so the binary and ternary Zn-based alloys with Mg, Mn as alloying elements have been developed and studied.In this paper, Zn-0.5 Mg-xMn (x = 0.5, 1.0, 1.5 wt%) alloys were prepared by backward extrusion approach.The Mg₂Zn₁₁ s phase exists in the Zn-0.5 Mg-xMn alloys.With the increase of Mn content, the average grain size of Zn-0.5 Mg-xMn alloys is obviously refined, and the MnZn₁₃ phase gradually increases and the texture strength is weakened.The yield strength, ultimate tensile strength, and elongation of Zn-0.5Mg-0.5Mn alloy are 258 MPa, 338 MPa, and 22.5 %, resp.The corrosion rate of Zn-0.5Mg-0.5Mn alloy is about 0.05 mm/y.The results indicate that the Zn-0.5Mg-0.5Mn alloy is expected to be a promising biodegradable biomaterial.

100 项与大连大学附属中山医院相关的药物交易

登录后查看更多信息

100 项与大连大学附属中山医院相关的转化医学

登录后查看更多信息